What do systematic reviews say?

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 85 participants
  Very low

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

Recombinant human thyrotropin‐aided radioiodine probably leads to higher hypothyroidism compared with radioiodine (moderate certainty).

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  RR 2.53 [1.52, 4.2]
  6 studies · 321 participants
  Moderate

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

Recombinant human thyrotropin‐aided radioiodine showed no clear difference in adverse events compared with radioiodine (low certainty).

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  RR 1.24 [0.94, 1.63]
  6 studies · 321 participants
  Low

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 268 participants
  Moderate

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Very low

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

The review found no eligible studies for this question.

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found